Latest International AIDS Vaccine Initiative Stories
CLEVELAND, March 27, 2012 /PRNewswire/ -- Innovators live at all levels of organizations, and often run companies of their own. These are the brilliant minds that NineSigma taps to solve the biggest, most perplexing challenges in the world, from developing an effective AIDS vaccine to making electricity accessible in developing countries. In addition, as more businesses commit to innovation as a growth strategy, new doors are opening for entrepreneurs, inventors and...
ATLANTA, March 20, 2012 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million (which are...
ATLANTA, March 7, 2012 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotech company specializing in the development of HIV/AIDS vaccines, announced the results of a study suggesting that scientists may be one step closer to a vaccine that protects against multiple exposures to HIV infections. The study results were unveiled by Dr. Robinson during a presentation in Seattle at the 2012 Conference on...
CLEVELAND, Feb. 21, 2012 /PRNewswire/ -- A collaboration between NineSigma and the International AIDS Vaccine Initiative (IAVI) is helping to advance HIV vaccine research by identifying new approaches to the design of a potential vaccine. A leading worldwide provider of innovation services, NineSigma has connected IAVI with some of the world's leading biomedical researchers, and helped it identify two scientists who will receive a total of $875,000 to develop solutions for...
PRINCETON, N.J., Feb. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary...
ORLANDO, Fla., Jan. 13, 2012 /PRNewswire-USNewswire/ -- On January 9, the Florida Consortium for HIV/AIDS Research (FCHAR) conducted its second annual summit in Orlando. Sixty prominent researchers from around the state gathered to advance a collaborative HIV/AIDS research agenda. Seventeen expert presenters participated in four audience-interactive panels covering ethics and three types of HIV/AIDS studies; clinical trials, epidemiological/behavioral investigations and basic science...
NEW YORK, Dec. 6, 2011 /PRNewswire/ -- Real estate mogul Elie Hirschfeld and Sarah Schlesinger, MD are attending Nobel Week Ceremonies in Stockholm Sweden. Schlesinger's scientific collaborator for the last 35 years was Ralph Steinman, MD who won the Nobel Prize this year in Medicine. Hirschfeld is attending as Schlesinger's guest, and serves on the Council of The Rockefeller University. Ralph Steinman is one of this year's three Nobel Laureates in Physiology or Medicine....
NEW YORK, Nov. 30, 2011 /PRNewswire-USNewswire/ -- AVAC today issued a three-part, science-based agenda for ending the AIDS epidemic within our lifetimes. The new report, titled The End?, is a unique strategic vision encompassing key steps to accelerate impact with existing HIV prevention tools, emerging strategies and longer term research. It identifies critical priorities in each of these areas and advances specific recommendations for both 2012 and for the next decade. "The past...
The findings advance AIDS vaccine development Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development. "What's unexpected and unique about this antibody is that it not only attaches to the sugar coating of the virus but also reaches through to grab...
The Findings Advance AIDS Vaccine Development LA JOLLA, Calif., Oct. 13, 2011 /PRNewswire-USNewswire/ -- Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development. "What's unexpected and unique about this antibody is that it not only attaches to the sugar...
